{"filing":{"accession_number":"0001193125-26-266078","cik":"0001819133","ticker":"TNGX","company_name":"Tango Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"d81492d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312526266078/d81492d8k.htm"},"events":[{"id":5685,"run_id":4979,"accession_number":"0001193125-26-266078","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Tango Therapeutics entered into an underwriting agreement on June 9, 2026 to conduct an underwritten public offering of 18.2 million shares of common stock and pre-funded warrants to purchase 1.8 million additional shares, with a 30-day overallotment option for 3 million more shares. The offering is expected to raise approximately $566.5 million in net proceeds. This is a material dilutive equity issuance that increases the share count and dilutes existing shareholders, disclosed under Item 1.01 as a material definitive agreement.","company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5995,"accession_number":"0001193125-26-266078","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Tango Therapeutics entered into an underwriting agreement on June 9, 2026 to conduct an underwritten public offering of 18.2 million shares of common stock and pre-funded warrants to purchase 1.8 million additional shares, with a 30-day overallotment option for 3 million more shares. The offering is expected to raise approximately $566.5 million in net proceeds. This is a material dilutive equity issuance that increases the share count and dilutes existing shareholders, disclosed under Item 1.01 as a material definitive agreement.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T21:23:06.345357+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5995,"accession_number":"0001193125-26-266078","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Tango Therapeutics entered into an underwriting agreement on June 9, 2026 to conduct an underwritten public offering of 18.2 million shares of common stock and pre-funded warrants to purchase 1.8 million additional shares, with a 30-day overallotment option for 3 million more shares. The offering is expected to raise approximately $566.5 million in net proceeds. This is a material dilutive equity issuance that increases the share count and dilutes existing shareholders, disclosed under Item 1.01 as a material definitive agreement.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T21:23:06.345357+00:00","company_name":"Tango Therapeutics, Inc.","ticker":"TNGX","filing_date":"2026-06-10"}]}